logo-loader

C4X Discovery shifts focus to immuno-inflammatory diseases

Last updated: 12:25 19 Feb 2024 GMT, First published: 06:02 15 Apr 2021 BST

Snapshot

  • C4XD: A biotechnology pioneer in immuno-inflammation  
  • C4X Discovery succeeding in the face of some tough market headwinds
  • C4X Discovery payment ‘strong validation’ of firm’s prowess - analyst
  • C4X Discovery "really well capitalised and focused" heading into new year
researcher

About the company

C4X Discovery Holdings PLC is a pioneering drug discovery company combining scientific expertise with cutting-edge drug discovery technologies to efficiently deliver world leading medicines.

The company has a highly valuable and differentiated approach to drug discovery through its enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders.

C4X Discovery's commercially attractive portfolio ranges from early-stage novel target opportunities to late-stage drug discovery programmes ready for out-licensing to partners and it has two commercially partnered programmes with one candidate in clinical development.

How it is doing

11 Jan 2024

C4X Discovery Holdings PLC (AIM:C4XD), a Manchester-based biotechnology company, is making significant strides in the field of immuno-inflammatory disease, executing a new and ‘evolutionary’ strategy.

The move forms part of the company’s strategy to focus on immuno-inflammatory pathways and to progress further along the development pathway, a core shift in its business model initiated last year. 

In an exclusive interview, the company’s Chief Scientific Officer (CSO) Nick Ray and Chief Business Officer Bhavna Hunjan shed light on its use of small molecule oral therapies to treat inflammatory and autoimmune diseases. 

In November 2022, C4XD secured a worldwide exclusive licence worth up to US$402 million for its NRF2 Activator programme, marking a significant milestone for the company, which is led by Chief Executive Clive Dix, who was the former Deputy Chair of the UK’s Vaccine Taskforce. 

03 Jan 2024

C4X Discovery Holdings PLC (AIM:C4XD) has reached what has been described as a "significant milestone" after receiving an US$11 million payment under its US$402 million deal with pharma giant AstraZeneca PLC (LSE:AZN).

Specifically, the financial landmark marks the progression of the NRF2 Activator programme, created by C4XD and outlicensed to AZ.

14 Dec 2023

C4X Discovery Holdings PLC (AIM:C4XD)’s latest financial results struck the right notes with equities analysts on Thursday, with Shore Capital Markets predicting considerable upside on current market valuations.

C4X already has licensing deals in place with some of the leading developers for its programmes, with ShoreCap reckoning the agreements with Sanofi and AstraZeneca could deliver up to US$800 million in milestones, with up to US$22 million in preclinical development milestones potentially converting in the near term.

Insight: C4X Discovery succeeding in the face of some tough market headwinds

19 Feb 2024

A marked decline in the value of AIM-listed healthcare stocks over the past two-and-a-half years belies the significant progress being made behind the scenes at these innovative companies.

A case in point is C4X Discovery Holdings PLC (AIM:C4XD), which has two licensing agreements under its belt with blue-chip partners, has sold an asset and, crucially, is funded for the foreseeable future.

What the brokers say

03 Jan 2024

News of C4X Discovery Holdings PLC (AIM:C4XD)’s latest payment from AstraZeneca PLC (LSE:AZN) solidifies and validates the company’s place as a skilled drug developer, analysts have said.

Following the firm’s update that US$11 million had been received under a deal worth up to US$400 million with AstraZeneca for the NRF2 activator programme, Shore Capital analysts backed aim-listed C4X.

“We see this as an important value inflection which should reinvigorate sentiment in the share,” the bank said in a note.

What management says

04 Jan 2024

 

C4X Discovery Holdings PLC (AIM:C4XD) Chief Business Officer Bhavna Hunjan and Chief Scientific Officer Nick Ray speak to Thomas Warner from Proactive after the drug discovery company announced receipt of a US$11 million payment under its US$402 million deal with pharma giant AstraZeneca PLC (LSE:AZN).

Specifically, the financial landmark marks the progression of the NRF2 Activator programme, created by C4XD and outlicensed to AZ. Nick Ray elaborates on NRF2, a molecule critical in regulating cellular oxidative stress and inflammatory responses, saying that the discovery has potential applications in various inflammatory diseases like COPD, sickle cell disease, and multiple sclerosis.

C4X Discovery "really well capitalised and focused" heading into new year

  C4X Discovery Holdings PLC (AIM:C4XD) Chief Business Officer Bhavna Hunjan and Chief Scientific Officer Nick Ray speak to Thomas Warner from Proactive after the drug discovery company announced receipt of a US$11 million payment under its US$402 million deal with pharma giant AstraZeneca...

on 4/1/24